

Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT W WX0000003827 M 07/08/1978 45 Y

		Refe	rral Testing				
			Collected: 09/25			: 09/25/2023	08:54
Test Name		<u>Result</u>	<u>E</u>	lag <u>Ref-Rar</u>	nges	<u>Units</u>	<u>Site</u>
JAK2 V617	'F Cascading Reflex	c					
Clinical Indication	on:	NA					QCRL
Specimen Sour		LAV					QCRL
Block/Specimer		NA					QCRL QCRL
JAK2 V617F Mu	utation	DETECT	ED /	AB			QURL
NC Tes Que 336	eference Range: DT DETECTED st Performed at: est Diagnostics Nicho 608 Ortega Highway n Juan Capistrano, CA		I Maramica	MD, PhD, M	BA		
CALR Exon 9 M	lutation	TNP					QCRL
NC Tes Que 336	ference Range: DT DETECTED st not performed. Not st Performed at: est Diagnostics Nicho 608 Ortega Highway n Juan Capistrano, CA	ols Institute	I Maramica	MD, PhD, M	ВА		
JAK2 Exon 12 M	Mutation	TNP					QCRL
	ference Range: DT DETECTED						
Tes MPL Exon 10 M	st not performed. Not lutation	indicated. TNP					QCRL
	ference Range: DT DETECTED						
Tes	st not performed. Not	indicated.					
CSF3R Exon 14	4/17 Mutation	TNP					QCRL
	eference Range: DT DETECTED						
Tes	st not performed. Not	indicated.					

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED



Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108

EXAMPLE, REPORT W WX0000003827 M 07/08/1978 45 Y

		Referral Te	stina		
			-	Received: 09/25/2023	3 08:54
<u>Test Name</u>	2	<u>Result</u>	Flag Ref-Ranges	<u>Units</u>	<u>Site</u>
Gene		SEE NOTE			QCRL
	JAK2				
Amino Acio	d	SEE NOTE			QCRL
	p.Val617Phe				
Mutation F	requency	SEE NOTE			QCRL
	20.1				
Mutation T	уре	SEE NOTE			QCRL
	missense				
Exon		SEE NOTE			QCRL
	Exon 14				
Nucleotide	Change	SEE NOTE			QCRL
	c.1849G>T				
Reference		SEE NOTE			QCRL
	COSM12600 Test Performed at: Quest Diagnostics N 33608 Ortega Highwa San Juan Capistrano	У	amica MD, PhD, MBA		
Interpretati	ion	SEE NOTE			QCRL
	JAK2 exon 12, CALR, mutational analysis	9G>T) mutation is detected MPL and CSF3R is not indi can be performed on seque nse (test code 92473).	cated. JAK2 V617F		
	This data was revie	wed and interpreted by Cha	rles Ma, PhD. HCLD(A	BB)	
Assay Deta	ails	SEE NOTE			QCRL

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F325000019	Or
WX000003827	W
Printed D&T: 09/25/23 08:59	

Ordered By: KAJAL SITWALA, MD, PhD VX00000000002365 Kajal V. Sitwala, MD, PhD - Medical Director Form: MM RL1 PAGE 2 OF 3



Example Client, XYZ123 1234 Warde Road Ann Arbor MI 48108 **EXAMPLE, REPORT W** WX0000003827 M 07/08/1978 45 Y

		Referr	al Testing				
		C	Collected: 09/25/2023	3 08:54	Received:	09/25/2023	08:54
<u>Test Name</u>		<u>Result</u>	Flag	Ref-Ranges	<u>s l</u>	<u>Jnits</u>	<u>Site</u>
le JA an ap ty be (S my es ex ex ch an MP in MP re Te DN Th ha Ca be cl Te Qu 33	titeReultFig MeRangesUnitsDistDistDistDistDistDistDistThis ECC-based advanced sequencing assay interrogates DNA from lakdocytes for the presence of mutations in codon 617 and exon 12 of JAK2, exon 9 of CALR, exon 10 (codons 505 and 515) of MPL and exons 14 and 17 of CSF3R. The sensitivity of mutation detection is approximately 5%, but may vary depending on the particular mutation type. Alterations outside of the tested areas of these genes will not be detected. Synonymous or known non-synonymous polymorphic changes (SNS) are not reported. JAK2 V617F mutation is associated with myeloproliferative neoplasms (MPNs), including polycythemia vera (PV), essential thrombocythemia (ET) and primary myelofiborsis (PMF); JAK2 exon 10 mutations with PY. CALR exon 9 indels with ET and PMF, MPL exon 10 mutations with PY and CSF3R mutations with atypical chronic myeloid leukemia (aCML), chronic neutrophilic leukemia (CNL) and other myeloid neoplasms. Increasing allele burden of JAK2 V617F in MPNs has been shown in a number of studies to be associated with increased symptoms including classification. To further evaluate for MPNs if this assay is negative, additional testing for DCA-BALI earrangement (test code 91065 or 12070) can be performed.Dist est neithed to GRCh37(hg19) for analysitDist est determined by Quest Diagnostics Nichols Institute San Jun for ber validated pursuant to the CLIA regulations and is used for or pristrano. It has not been cleared or approved by FPA. This assay has been validated pursuant to the CLIA regulations and is used for or pristrano. It has not been cleared or approved by FPA. This assay has been validated pursuant to the CLIA regulations and is used for or pristrano. It has not been cleared or approved by FPA. This assay has been vali						
Billing Only - C	CALR Exon 9 Mutation	.TNP					QCRL
Billing Only - J/	AK2 exon 12 Mutation	.TNP					QCRL
Billing Only - M	IPL Exon 10 Mutation	.TNP					QCRL
Billing Only - C	SF3R Exon 14/17 Mutation	.TNP					QCRL
		QCRL: QUEST DIAGN	OSTICS REFERENCE LAB CA	PISTRANO 33608	Ortega Highway S		rming Site: CA 92675
				d Date: 202			KCR

Reported Date: 2023.09.25 8:58 JAKCR

Ordered By: KAJAL SITWALA, MD, PhD WX0000000002365